Journal of cancer research and therapeutics
-
Meta Analysis
The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
The serum level of Cyfra21-1 was always elevated in patients with nonsmall cell lung carcinoma. The aim of this meta-analysis was to evaluate the serum Cyfra21-1 as a biomarker in the diagnosis of nonsmall cell lung cancer (NSCLC). ⋯ With published data, the serum Cyfra21-1 was a useful biomarker for diagnosis of NSCLC.